- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Bile Salt.
Displaying page 1 of 1.
EudraCT Number: 2020-001961-34 | Sponsor Protocol Number: RDG-1/PBC | Start Date*: 2021-02-02 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of RhuDex granules with placebo in the treatment of primary biliary cholangitis | |||||||||||||
Medical condition: Primary biliary cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) HU (Prematurely Ended) SK (Prematurely Ended) NL (Prematurely Ended) BE (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002434-10 | Sponsor Protocol Number: BVT.BSSL-021 | Start Date*: 2007-10-17 |
Sponsor Name:Biovitrum AB (publ.) | ||
Full Title: A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to pasteurized breast milk versus placebo during one week of treatment in preterm infants born before week 32... | ||
Medical condition: Enzyme replacement therapy in pre-term infants. Reduced fat uptake capabilities due to prematurity of pre-term infants | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-010163-16 | Sponsor Protocol Number: 08/0285 | Start Date*: 2009-06-05 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: Bile salt manipulation as a novel treatment for Crohn’s disease: a single centre open label pilot study of atorvastatin and colesevalam in patients with active ileal Crohn’s disease | ||||||||||||||||||
Medical condition: Active Crohn's disease affecting the ileum | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003631-37 | Sponsor Protocol Number: UDC1 | Start Date*: 2017-01-24 |
Sponsor Name:Universitaire ziekenhuis Leuven | ||
Full Title: Therapeutic effect of ursodeoxycholic acid on duodenal permeability and meal related sensory motor function in functional dyspepsia patients | ||
Medical condition: Functional dyspepsia (FD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023909-35 | Sponsor Protocol Number: BVT.BSSL-030 | Start Date*: 2011-06-24 | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum AB (publ) | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Phase 3 Study Comparing rhBSSL and Placebo Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants Born Before Wee... | |||||||||||||
Medical condition: Prevention of growth retardation due to lack of bile salt-stimulated lipase in enteral nutrition | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) HU (Completed) FR (Ongoing) CZ (Completed) PL (Prematurely Ended) ES (Prematurely Ended) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001317-28 | Sponsor Protocol Number: ABBA-2 | Start Date*: 2015-07-30 |
Sponsor Name:UMC Utrecht | ||
Full Title: A B2-agonist as a CFTR activator in CF - Part 2 | ||
Medical condition: Cystic fibrosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001642-10 | Sponsor Protocol Number: SMT19969/C005 | Start Date*: 2019-03-13 | |||||||||||
Sponsor Name:Summit (Oxford) Limited | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment ... | |||||||||||||
Medical condition: Clostridium difficile infection (CDI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Completed) LT (Completed) BE (Prematurely Ended) DE (Completed) CZ (Completed) ES (Ongoing) FR (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013348-35 | Sponsor Protocol Number: 7915 | Start Date*: 2009-08-04 | |||||||||||||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||||||||||||
Full Title: (Patho)Physiological aspects of the bile salt-FXR-FGF19-axis: potential consequences in Crohn's disease. | |||||||||||||||||||||||
Medical condition: Patients with quiescent Crohn’s colitis, defined as a Crohn’s Disease Activity Index <150 ; non-IBD patients will serve as disease controls. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002423-33 | Sponsor Protocol Number: BVT.BSSL-020 | Start Date*: 2007-10-30 | |||||||||||
Sponsor Name:BIOVITRUM AB | |||||||||||||
Full Title: A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to infant formula versus placebo during one week of treatment in preterm infants born before week 32 of gesta... | |||||||||||||
Medical condition: Enzyme replacement therapy in pre-term infants. Reduced fad uptake capabilities due to prematurity of pre-term infants | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002833-13 | Sponsor Protocol Number: AMT-101-203 | Start Date*: 2021-02-05 | |||||||||||
Sponsor Name:Applied Molecular Transport Inc. | |||||||||||||
Full Title: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Exploratory, Phase 2 Study of the Efficacy and Safety of Oral AMT-101 in Combination with Adalimumab in Subjects with Moderate to Sev... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000824-17 | Sponsor Protocol Number: BT-11-202 | Start Date*: 2021-05-26 | |||||||||||
Sponsor Name:Landos Biopharma Inc. | |||||||||||||
Full Title: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn’s Disease | |||||||||||||
Medical condition: Patients with Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended) HR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000047-31 | Sponsor Protocol Number: AMT-101-202 | Start Date*: 2020-08-03 | |||||||||||
Sponsor Name:Applied Molecular Transport Inc. | |||||||||||||
Full Title: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) HU (Completed) DE (Completed) BG (Completed) IT (Ongoing) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-005086-39 | Sponsor Protocol Number: BT-11-201 | Start Date*: 2019-10-28 | ||||||||||||||||
Sponsor Name:Landos Biopharma Inc. | ||||||||||||||||||
Full Title: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis | ||||||||||||||||||
Medical condition: Mild to Moderate Ulcerative Colitis Inflammatory bowel disease (IBD) is an autoimmune disease of the gastrointestinal (GI) tract with unknown etiology that encompasses 2 primary clinical manifesta... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) PL (Completed) HR (Completed) BG (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.